The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Dr. Reddy’s partners with Henlius for commercialization of HLX15 (daratumumab) biosimilar in the U.S. and Europe
Feb 06, 2025•over 1 year ago
Contract Type
partnership
HyderabadBiotechnologyHealth CarePharmaceutical
Description
Dr. Reddy’s Laboratories and Henlius have entered into a partnership agreement for the commercialization of HLX15, a biosimilar candidate to Darzalex® & Darzalex Faspro®. The collaboration aims to make the daratumumab biosimilar available to patients in the U.S. and Europe, leveraging Dr
Company Information
Company
Dr. Reddy's Holdings Limited
Location
Hyderabad, Telangana, India
About
Dr. Reddy's Holdings Limited is the holding company for Dr. Reddy's Laboratories. It serves as an investment and management organization within the pharmaceutical sector. The company plays a crucial role in facilitating financial and operational support for its subsidiary. It aims to enhance value for shareholders and promote sustainable growth.
Predictive Intelligence
Strategic
ML-powered predictions for Dr. Reddy's Holdings Limited's next move
HyderabadBiotechnologyHealth CarePharmaceutical